Exploiting epigenetic vulnerabilities for cancer therapeutics.
about
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug SensitivityCancer chemoprevention: current state of the artGenetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosisApproaches to identifying synthetic lethal interactions in cancer.BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer.Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.Regulation of human genome expression and RNA splicing by human papillomavirus 16 E2 protein.Genome-wide methylation analysis of DNMT3B gene isoforms revealed specific methylation profiles in breast cell lines.KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.What is the future of bromodomains in targeted drug development?Lifting Up the HAT: Synthetic Lethal Screening Reveals a Novel Vulnerability at the CBP-p300 Axis.The Role of DNA Methylation in Cancer.
P2860
Q28553888-06646BD4-E615-4BDE-899E-9FBA81EABA6FQ33783754-58C461FA-4B87-41A7-8F74-E0EC0192D6E9Q33823065-553E5A41-AFD9-43C2-B348-EC20B58CA977Q34608239-8148603A-A5A9-461D-8A52-C662F1315629Q34797680-7DE260F2-EB79-4CDC-8D57-694FECB45998Q35147669-3503940E-52BA-4F57-B0EC-AB1349423BD6Q35647469-92620D53-F7A7-46FC-850F-177E00649955Q35762941-5DBB39A8-8527-4143-B25F-B308323787F0Q35764577-5E40B0E7-F85B-41D8-AD91-D80F8F5DA02BQ38476564-791EA1A3-80BA-444D-A5BE-8051324BF71AQ38547122-B0AC09BE-7543-4976-BE6A-72091B5E36A0Q38702411-E20BE3AA-114A-45D9-A46B-853DD9009FEEQ38706007-265DAB9A-8759-4FC5-9259-DFF76BF8EBF4Q38735583-D588CF8D-56D5-494B-8BC3-DCA87E2A1402Q38828275-152631C0-CACA-4B7A-9780-ECFC1C8CC1F7Q38952574-359E9DD5-E22C-447E-9E54-DB0B0E56F66BQ38965368-DF964237-4C3B-421A-A1C0-9D398EF53620Q39430136-8D52146E-11FB-4718-9AE4-A0D3594C7F36Q41084396-63DC4632-7D63-4D63-9975-5252195FB6C1Q47155915-9BB78C94-F9E0-49BF-A4A5-5732ED2FC073Q48808733-6E7B976C-4DA0-4692-9AA4-9311B4CB84F1Q50326811-BB47E51C-EF94-412C-B431-713F5E35977FQ52966734-FA1AA853-A138-4F05-95D6-ABE0255D0203
P2860
Exploiting epigenetic vulnerabilities for cancer therapeutics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Exploiting epigenetic vulnerabilities for cancer therapeutics.
@en
type
label
Exploiting epigenetic vulnerabilities for cancer therapeutics.
@en
prefLabel
Exploiting epigenetic vulnerabilities for cancer therapeutics.
@en
P2093
P50
P1476
Exploiting epigenetic vulnerabilities for cancer therapeutics.
@en
P2093
Barbara Mair
Sebastian M B Nijman
Stefan Kubicek
P304
P356
10.1016/J.TIPS.2014.01.001
P577
2014-02-12T00:00:00Z